Business
Tiziana Life Sciences Promotes Matthew W. Davis, MD, RPh to Chief Operating Officer
NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing
About this update from Tiziana Life Sciences Ltd
[{"type":"text","content":"NEW YORK, June 13, 2023 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, is pleased to announce the appointment of Matthew Davis, MD, RPh as its new Chief Operating Officer (COO). Dr. Davis, who also serves as the Chief Medical Officer (CMO), will now take on this additional role to further drive the company's growth and strategic initiatives and will report to Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana. As the Chief Operating Officer, Dr. Davis will be responsible for overseeing Tiziana Life Sciences' day-to-day operations, including research and development, manufacturing, clinical trials, and commercialization efforts. His extensive experience in the biotechnology industry, coupled with his deep understanding of medical affairs, will be invaluable in advancing the company's pipeline and achieving key milestones. \"Matthew's promotion from Chief Medical Officer to Chief Operating Officer is a testament to his exceptional leadership skills and his significant contributions to Tiziana Life Sciences,\" said Gabriele Cerrone, Executive Chairman. \"His expertise in both clinical and operational aspects of the biotech industry will be instrumental in driving the company's growth and bringing our promising therapeutic candidates to patients in need.\" During his tenure as Chief Medical Officer, Dr. Davis played a pivotal role in the continued development and progression of Tiziana Life Sciences' therapeutic programs. His strategic insights and dedication to improving patient outcomes have been instrumental in advancing the companies lead asset foralumab into a phase 2 trial in non-active secondary progressive multiple sclerosis this year and the company's mission to develop innovative treatments for various CNS diseases. \"I am honored to take on the role of Chief Operating Officer at Tiziana Life Sciences,\" said Matthew Davis. \"I am excited to continue to work closely with the highly talented research and development team of Drs. Jules Jacobs and Vaseem Palejwala and build upon the strong foundation we have established. Together, as a company we will continue to drive the development and commercialization of transformative therapi...